ZSCAN4 Marker for Pancreatic Stem Cell Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The identification of resident stem cells in the pancreas is hindered by a low rate of spontaneous self-renewal and the lack of specific tissue stem cell markers, making it difficult to isolate and utilize pancreatic stem cells for treating diabetes.
Innovation Solution
ZSCAN4 is identified as a marker for rare stem/progenitor cells in the adult human pancreas, allowing for the isolation and expansion of these cells for diabetes treatment through detecting ZSCAN4 expression and transplanting or delivering ZSCAN4 proteins/nucleic acids to increase their population.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to identify pancreatic stem cells, then the process is straightforward, but the identification fails due to low self-renewal rate and lack of specific markers
Solution Approach 1:
The patent uses ZSCAN4 as an intermediary marker to indirectly identify pancreatic stem cells. Since direct identification of stem cells is difficult due to their rarity and lack of specific markers, ZSCAN4 serves as a detectable mediator that correlates with stem cell presence, enabling identification without directly observing the stem cells themselves
Solution Approach 2:
The patent replaces conventional mechanical/isolating methods with molecular detection methods. Instead of physically separating stem cells based on morphology or culture characteristics, the invention uses molecular biology techniques (PCR, in situ hybridization, immunohistochemistry) to detect ZSCAN4 expression, substituting physical separation with chemical/molecular detection
2Adaptability or versatility
If the pancreas is used for stem cell research, then diabetes treatment is possible, but the low self-renewal rate limits stem cell availability
Solution Approach 1:
The patent performs preliminary identification and isolation of ZSCAN4-expressing cells before therapeutic application. By detecting and isolating these cells in advance from pancreatic tissue, the invention creates a reservoir of potential stem cells that can be expanded and differentiated for future diabetes treatment, addressing the quantity limitation proactively
Solution Approach 2:
The patent changes the detection parameter from conventional stem cell markers to ZSCAN4 expression. This parameter change enables the identification and isolation of rare pancreatic stem cells that would otherwise be undetectable, thereby increasing the available quantity of stem cells for therapeutic use
3Ease of operation
If specific stem cell markers are developed, then isolation becomes easier, but the development time and complexity increase
Solution Approach 1:
The patent demonstrates that ZSCAN4 serves multiple functions: it is a marker for embryonic stem cells, a marker for pancreatic stem cells, and a target for therapeutic intervention. This multi-functionality simplifies the overall approach by using a single molecule for multiple purposes, reducing the need for developing separate markers for different applications
Data Source
AI summary
ZSCAN4, a gene expressed in ES cells and 2-cell stage embryos, has been previously shown to regulate telomere elongation and genome stability in mouse ES cells. It is disclosed herein that in the adult human pancreas, a small number of ZSCAN4-positive cells are present among cells located in the islets of Langerhans, acini, and ducts. These data disclosed herein indicates that expression of ZSCAN4 is a marker for rare stem/progenitor cells in adult human pancreas. Thus, provided herein is a method of isolating pancreatic stem cells or progenitor cell from a sample by detecting expression of ZSCAN4. Also provided is a method of treating diabetes by isolating ZSCAN4+ pancreatic stem cells or progenitor cells, expanding the cells in vitro and transplanted the expanded cells into the subject. The expanded ZSCAN4+ cells can optionally be differentiated into pancreatic β cells before transplanting the cells into the subject. Further provided is an in vivo method of expanding a population of pancreatic stem cells or progenitor cells in a subject by delivering a ZSCAN4 protein, a ZSCAN4 nucleic acid sequence, or an agent that increases expression of ZSCAN4 to the pancreas of the subject.